Fibrosis in Chronic and Delayed Myocardial Infarction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-90
SponsorUniversity of Edinburgh
About this trial
In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following any injury to the heart muscle and the investigators aim to identify this process early and in its active state. This will be examined by using a radiotracer 68Ga-FAPI or 18F-AlF-FAPI and PET-MRI or PET-CT.
Eligibility criteria
Qualifiers
Male or female above the age of 50 years old
Provision of informed consent prior to any study specific procedures
25 patients with symptomatic severe aortic stenosis (peak velocity >4.0 m/s)
25 patients with moderate aortic stenosis (peak velocity 3.0-4.0 m/s)
Disqualifiers
Inability or unwilling to give informed consent.
History of claustrophobia or feeling of inability to tolerate supine position for the MRI scans.
Impaired renal function with eGFR of <30 mL/min/1.73m2.
Women who are pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- 68Ga-FAPI and 18F-AlF-FAPI PET-MR
Treatment groups
180 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov